{"transactions":[{"id":689037,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, OBU"}}],"security":"American Depositary Shares","published_at":"2026-08-13T01:45:10.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":50012,"price":17.1,"value":855205.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":252010,"source":{"system":"sec-edgar","filing":"0001493152-26-037502","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000149315226037502/ownership.xml","form_type":"4"}},{"id":714589,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, OBU"}}],"security":"American Depositary Shares","published_at":"2026-07-06T22:02:36.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":43886,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027."}],"balance_after":302022,"source":{"system":"sec-edgar","filing":"0001395064-26-000247","document":"wk-form4_1783375354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000247/wk-form4_1783375354.xml","form_type":"4"}},{"id":737522,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:31:08.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":6.21,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-271171","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526271171/ownership.xml","form_type":"4"}},{"id":737521,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-15T20:31:08.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date."}],"balance_after":36000,"source":{"system":"sec-edgar","filing":"0001193125-26-271171","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000119312526271171/ownership.xml","form_type":"4"}},{"id":798711,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, OBU"}}],"security":"American Depositary Shares","published_at":"2026-04-28T10:06:08.000Z","date":"2026-04-27","kind":"grant","planned":false,"acquired":true,"shares":64988,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 1, 2023, the reporting person was granted an award of restricted stock units (RSUs), which vest in the form of American Depositary Shares based upon the achievement of the specified performance metrics, including core revenue, core operating profit, and important R&D milestones.  On April 27, 2026, the Compensation Committee of the Board of Directors determined the number of RSUs to be awarded based on these performance metrics, which amount is reported above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 150,790 restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share.  The RSUs vest on the following schedule: July 1, 2026 (105,044 shares), July 1, 2027 (30,564 shares) and July 1, 2028 (15,182 shares)."}],"balance_after":258136,"source":{"system":"sec-edgar","filing":"0001395064-26-000132","document":"wk-form4_1777370765.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395064/000139506426000132/wk-form4_1777370765.xml","form_type":"4"}},{"id":1182739,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T20:02:51.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in three substantially equal annual installments beginning on March 31, 2026, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":29000,"derivative":{"exercise_price":5.86,"expiration_date":"2035-03-31","underlying":"Common Stock","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0000950170-25-049279","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025049279/ownership.xml","form_type":"4"}},{"id":1182738,"issuer":{"id":5142,"kind":"organization","name":"Aura Biosciences, Inc."},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-02T20:02:51.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit (\"RSU\") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on April 15, 2026, subject to the Reporting Person's continued service as of each such vesting date."}],"balance_after":21000,"source":{"system":"sec-edgar","filing":"0000950170-25-049279","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025049279/ownership.xml","form_type":"4"}},{"id":1492556,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:35:41.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the \"Arrangement Agreement\"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden (\"Parent\") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act (\"Purchaser\"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the \"Shares\") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the \"Effective Time\"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the \"Cash Consideration\") plus (ii) one contingent value right (each, a \"CVR\") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":4.16,"underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0000950170-24-068912","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068912/ownership.xml","form_type":"4"}},{"id":1759888,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":24045,"kind":"person","name":"Bitetti Teresa Marie","position":1,"cik":"0001977608","reported_name":"Bitetti Teresa Marie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-16T16:59:24.000Z","date":"2023-10-16","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 36 substantially equal monthly installments starting on November 16, 2023."}],"balance_after":34000,"derivative":{"exercise_price":4.16,"expiration_date":"2033-10-16","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-23-052878","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919123052878/doc4.xml","form_type":"4"}}]}